Icon Oncology Holdings (Pty) Ltd, including all its subsidiaries and associated Companies, is excited to announce that Anthony Pedersen, currently CEO of Medscheme, has been appointed as the Group CEO of Icon. Anthony will assume the role, based at the company’s Head Office in Cape Town, effective 1 January 2020, the commencement of the group’s new fiscal year.
Anthony’s appointment is the culmination of a rigorous search and selection process driven by the Board, following the resignation of Dr Jacques Snyman, to identify a dynamic and experienced CEO capable of steering Icon into the next exciting phase of its development.
“I am delighted to welcome Anthony to the team”, said Scott Brodsky, Chairman of the Board. “He brings deep expertise, passion and insight about the South African healthcare landscape. His knowledge of the industry, familiarity with the Icon model, ability to scale a business, together with his strong core values, made Anthony the perfect choice to lead Icon”, said Scott.
Anthony Pedersen comes with a wealth of healthcare experience
Anthony is a qualified Chartered Accountant with more than 20 years’ local and international leadership experience in the healthcare industry. He started his healthcare career in 1999, at Momentum Medical Scheme Administrators (Pty) Ltd, where he eventually progressed to Chief Financial Officer (CFO) of Momentum Group Benefits. In 2007, he relocated to Mauritius, where he established a new insurance business for the group, before joining Afrocentric in 2010. He has taken on a number of leadership roles at Afrocentric, including MD of International Operations, COO of Medscheme South Africa, MD of Helios IT solutions, and most recently as CEO of Medscheme, where he heads up the South African, African and International operations for the company.
Anthony currently lives in Johannesburg with his wife and two adult children. The family will relocate to Cape Town ahead of his commencement with Icon in January 2020.
Scott Brodsky will continue to work closely with the Executive team until Anthony’s formal commencement in January 2020.
The Board is also extremely grateful for Jacques’ contributions to the company during his tenure as CEO and the Board looks forward to his continued contribution until the end of the year in his capacity as consultant.
From the chairman on behalf of the Board of Icon Oncology Holdings.